New research has identified the specific biological mechanism behind the muscle dysfunction found in myotonic dystrophy type 1 (DM1) and further shows that calcium channel blockers can reverse these ...

Ibutilide is the only Food and Drug Administration-approved intravenous drug for the rapid termination of atrial fibrillation and flutter. Its mechanism of action is undecided. The drug has been ...

New research has identified the specific biological mechanism behind the muscle dysfunction found in myotonic dystrophy type 1 (DM1) and further shows that calcium channel blockers can reverse these ...

Zalicus Initiates the First of Two Phase 2a Studies with Z160, a First-in-Class, Oral, State-Dependent, Selective N-type Calcium Channel Blocker, for the Treatment of Chronic Neuropathic Pain (NASDAQ: ...

When you have atrial fibrillation, the two upper chambers of your heart (atria) don't beat in sync with the two lower chambers (ventricles). This makes your heart beat out of rhythm and sometimes very ...

Chicago, IL - A new analysis of data from the Women's Health Initiative Observational Study shows that among the more than 30 000 women with uncomplicated hypertension in this cohort, treatment with ...

A regularly prescribed class of heart medications might be capable of treating one of the most common forms of muscular dystrophy, a new study in mice suggests. Myotonic dystrophy type 1 (DM1) is ...

Introduction The clinical management of Obstructive Hypertrophic Cardiomyopathy remains challenging, and the phase III EXPLORER-HCM trial has demonstrated that the novel cardiac myosin inhibitor ...

Long-term use of a calcium-channel blocker to treat hypertension (high blood pressure) is associated with higher breast cancer risk, according to a report published by JAMA Internal Medicine, a JAMA ...

Active ingredient: Clevidipine butyrate emulsion 0.5 mg/mL; solution for IV infusion; contains lipids 0.2 g/mL (soybean oil, egg phospholipids). Indication: To reduce BP when oral therapy is not ...